These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30013569)

  • 1. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.
    King LA; Lameris R; de Gruijl TD; van der Vliet HJ
    Front Immunol; 2018; 9():1519. PubMed ID: 30013569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
    Hung JT; Huang JR; Yu AL
    J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy.
    Araki M; Miyake S; Yamamura T
    Curr Med Chem; 2008; 15(23):2337-45. PubMed ID: 18855664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of NKT cells in cancer immunotherapy.
    Bae EA; Seo H; Kim IK; Jeon I; Kang CY
    Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel in vitro invariant natural killer T cell functional assays.
    Balasko A; Graydon C; Fowke KR
    J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma.
    Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J
    J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
    Song W; van der Vliet HJ; Tai YT; Prabhala R; Wang R; Podar K; Catley L; Shammas MA; Anderson KC; Balk SP; Exley MA; Munshi NC
    Clin Cancer Res; 2008 Nov; 14(21):6955-62. PubMed ID: 18980990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.
    Zhang L; Donda A
    Front Immunol; 2017; 8():1417. PubMed ID: 29163493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.
    Corgnac S; Perret R; Zhang L; Mach JP; Romero P; Donda A
    J Immunother Cancer; 2014; 2(1):39. PubMed ID: 25426294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
    Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
    Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting iNKT Cell Antitumor Immunity with α-GalCer/CD1d-scFv Fusion Proteins.
    Zhang L; Donda A
    Methods Mol Biol; 2021; 2388():175-180. PubMed ID: 34524672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
    Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
    Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
    Seki T; Liu J; Brutkiewicz RR; Tsuji M
    Anticancer Res; 2019 Feb; 39(2):549-555. PubMed ID: 30711929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
    Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
    Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
    Berkers CR; Ovaa H
    Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
    Yang G; Artiaga BL; Lewis ST; Driver JP
    Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 6B11 mAb and α-GalCer-loaded CD1d dextramers for detection of iNKT cells by flow cytometry.
    Lenart M; Gruca A; Mueck A; Rutkowska-Zapała M; Surman M; Szaflarska A; Kobylarz K; Baran J; Siedlar M
    J Immunol Methods; 2017 Jul; 446():1-6. PubMed ID: 28365328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
    Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species-specific activity of glycolipid ligands for invariant NKT cells.
    Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
    Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.